FLEXIBLE ADMINISTRATION TO OPTIMIZE THE PATIENT EXPERIENCE
Administration overview
Simple, convenient, and ready to use
Hizentra is the first and only SCIg prefilled syringe approved for in-home administration.
Compared with vials, prefilled syringes may1:
- Shorten preparation time
- Be directly compatible with certain infusion pumps, depending on size*
- Reduce waste
*An adaptor may be provided by the specialty pharmacy if necessary. However, all sizes can be transferred to a pump-compatible syringe using a transfer device.
1 g (5 mL), 2 g (10 mL), 4 g (20 mL), 10 g (50 mL)
Administering Hizentra therapy
- A Hizentra dose may be infused into multiple injection sites
- In the US clinical study, most infusions used ≤4 sites. Up to 8 sites may be used simultaneously per infusion
- More than one infusion device can be used
- Infusion sites should be at least 2 inches apart
- Change the actual site of infusion with each administration†
- Subcutaneous needles are smaller than IV needles2,3
- Depending on a patient’s size and weight, needles as short as 4 mm or as long as 14 mm can be used‡
- Commonly used needle sizes in adults are 9 mm and 12 mm
- Hizentra should be administered subcutaneously only. Do not administer intravenously
- Hizentra can be administered daily up to every 2 weeks for PI using infusion pump(s) and subcutaneous needle(s)
- Please see the full Prescribing Information for a complete list of all necessary supplies
Recommended Infusion Sites
†New sites should be at least 1 inch from a previous infusion site.
‡It’s important to choose an infusion needle long enough to reach the subcutaneous tissue.
INFUSION OPTIMIZATION
Personalizing administration further
Supplies
- Needle size and rate-control tubing can be customized per patient to optimize their experience3
- Consider changing one variable at a time (eg, rate, volume, ancillary supplies, or infusion site[s]) when tailoring treatment for your patient
Comfort
- During infusion training, nurses can help patients select an optimal needle length§
- The number of sites can be customized (up to 8 can be used in parallel) and should be rotated with each infusion
Infusion duration
- Volume and infusion rate per site can be adjusted after initial infusion as tolerated, which may decrease infusion time and number of sites¶
- Up to 8 infusion sites can be used simultaneously, with at least 2 inches between sites
§It’s important to use an infusion needle long enough to reach the subcutaneous tissue. Appropriate needle length may vary depending on the patient's body composition and the infusion site location.2
¶For the first infusion of Hizentra, do not exceed a volume of 15 mL/site or a flow rate of 15 mL/h/site. For subsequent infusions, the volume per site and flow rate may be increased to 25 mL/site and 25 mL/h/site respectively, as tolerated.
Monitor the patient’s clinical response and adjust therapy based on patient need
Over time, the dose may have to be adjusted to achieve the desired results.
- To determine if a dose adjustment is needed, measure the patient’s serum IgG trough level 2 to 3 months after transitioning to Hizentra2
- The goal is to achieve a systemic serum IgG exposure (area under the concentration-time curve) not inferior to that of the previous IVIg or SCIg treatment
Use the patient’s clinical response as the primary consideration in dose adjustment
- Additional dosage increments may be indicated based on the patient’s clinical response (infection frequency and severity)
- To learn how to adjust the dose, please see the full Prescribing Information
Infusion videos
See how easy self-administration can be with Hizentra prefilled syringes
How to Self-Infuse Hizentra
Hizentra can be dosed daily up to every 2 weeks for PI using an infusion pump and relatively small needle(s).
The Benefits of Prefilled Syringes vs Vials
- Simple, convenient, and ready to use
- May reduce steps and effort compared to vials
- Wide range of sizes to meet patient needs
“When I first started with Hizentra, I had hope for the first time I could now do my infusions at home while I took care of my family and be present and not lose time away from my children and my husband.”
MelaineReal Hizentra user and patient advocate
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
Abbreviations: Ig, immunoglobulin; IgG, immunoglobulin G; IV, intravenous; IVIg, intravenous immunoglobulin; PI, primary immunodeficiency; SCIg, subcutaneous immunoglobulin.
References: 1. Kafal AR, Vinh DC, Langelier MJ. Expert Opin Drug Deliv. 2018;15(12):1199-1209. doi:10.1080/17425247.2018.1546692 2. Sizes of injection needles: a complete guide. VialLabeller. Updated August 22, 2024. Accessed July 24, 2026. https://viallabeller.com/sizes-of-injection-needles/ 3. Radley E, Hendricks L, Barrett L, Murphy E, Sivamurthy K. Real-world experience of needle length use based on BMI for IgPro20 administration. Poster P104 presented at: Immunoglobulin National Society (IgNS); 2023 Oct 5-8; Denver, CO.
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.